Suppr超能文献

长期腹腔通路及一种新型通路导管的描述

Long-term intraperitoneal access with description of a new access catheter.

作者信息

Pedro Villarejo Campos, Edward Bruce-White, Mariano García Arranz, Qian Siyuan, Antonio Pedro, Cascales Campos, Damián García Olmo, Alberto Martínez Albalat

机构信息

Department of Surgical Oncology, Jiménez Díaz Foundation Institute for Health Research, Madrid, Spain.

出版信息

J Surg Oncol. 2024 Nov;130(6):1390-1394. doi: 10.1002/jso.27843. Epub 2024 Aug 25.

Abstract

BACKGROUND AND OBJECTIVES

Intraperitoneal chemotherapy can be administered as a single dose associated with hyperthermia (HIPEC) or in successive doses under normothermic conditions, such as early postoperative intraperitoneal chemotherapy (EPIC) or normothermic intraperitoneal chemotherapy (NIPEC or NIPEC-LT). Repetitive administration of intraperitoneal chemotherapy over a prolonged period may be associated with catheter-related complications, which are the primary cause of treatment interruption. This study aims to introduce and evaluate an innovative catheter system designed to mitigate these issues.

METHODS

Using a porcine experimental model, we tested a new catheter for long-term intraperitoneal access. Sixteen animals underwent catheter implantation followed by normothermic recirculation of peritoneal dialysis solution. Catheter functionality and any complications were monitored throughout successive treatment cycles.

RESULTS

The new catheter system demonstrated optimal recirculation and maintained its functionality throughout successive treatments, without complications. Catheter replacement with a guidewire was successful, ensuring continued efficacy.

CONCLUSIONS

The innovative catheter system shows promise in reducing complications and improving compliance in successive intraperitoneal chemotherapy doses, justifying further clinical trials to confirm its efficacy in patients.

摘要

背景与目的

腹腔内化疗可作为与热疗联合的单剂量给药(热灌注化疗,HIPEC),也可在常温条件下分多次给药,如术后早期腹腔内化疗(EPIC)或常温腹腔内化疗(NIPEC或NIPEC-LT)。长时间重复进行腹腔内化疗可能会出现与导管相关的并发症,这是治疗中断的主要原因。本研究旨在介绍并评估一种旨在减轻这些问题的创新导管系统。

方法

我们使用猪实验模型测试了一种用于长期腹腔内通路的新型导管。16只动物接受了导管植入,随后进行腹膜透析液的常温再循环。在连续的治疗周期中监测导管功能及任何并发症。

结果

新导管系统在连续治疗过程中显示出最佳的再循环效果,并保持其功能,无并发症发生。通过导丝成功更换导管,确保了持续疗效。

结论

这种创新的导管系统在减少连续腹腔内化疗剂量的并发症和提高依从性方面显示出前景,有理由进行进一步的临床试验以证实其在患者中的疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d98/11826025/7855e739d213/JSO-130-1390-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验